Home / Medicine / Abseamed

Abseamed

Marketed in 30 countries across the European Economic Area and neighbouring markets, Abseamed is a brand of epoetin alfa, classified within the antianemic, erythropoietic, and hematopoietic categories. The brand sits within the family of biologic medicines used to support red blood cell production, and the country footprint reflects its primary distribution through European regulatory channels.

Epoetin alfa is used in the management of anemia in a range of clinical contexts, including anemia associated with chemotherapy, anemia in patients undergoing hemodialysis, anemia related to myelodysplastic conditions or lymphoma, and the reduction of allogeneic blood transfusion requirements around major surgery. Iron status is also relevant in this therapeutic area, since adequate iron is needed for the response to erythropoietic therapy. The structured indication list further down this page details the registered uses recognised by the regulators in the markets where Abseamed is sold.

The country cluster is distinctly European — examples include Germany, Finland, Greece, Ireland, and Hungary — and a traveller carrying Abseamed outside this region may not encounter the same brand on local pharmacy systems. Other epoetin alfa products and biosimilars circulate internationally under different brand names, and other erythropoiesis-stimulating agents in the same broad pharmacological class are registered in markets worldwide. A local pharmacist or treating specialist is well placed to identify what is available regionally.

Erythropoietic therapy is highly individualised and tied closely to laboratory monitoring and the underlying condition being managed. Anyone receiving Abseamed who is travelling, relocating, or trying to identify a local equivalent should coordinate that with the healthcare team responsible for their care rather than treating it as a routine substitution at the pharmacy counter.

Countries
Austria Belgium Bulgaria Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Liechtenstein Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom
Diseases
Chemotherapy Anemia Surgery Lymphoma Hemodialysis Iron deficiency Myelodysplastic diseases Blood transfusion Peritoneal dialysis Renal failure Cancer,multiple myeloma Cancer,plasma cell myeloma Chronic renal failure
Ingredients
Epoetin alfa
Drug Actions
Antianemic Erythropoietic Hematopoietic

Drugs with the same active ingredients

Eritrogen Hemax Hypercrit Eprex Binocrit Epoetin alfa hexal Erypo Epoetin Epoetin (epoetin alfa) Epogen Procrit Eporon Epiao Epokine Eposis Espogen Hema-plus Renogen Aeprine Binokrit

Abseamed

Special precautions for disposal and other handling

The product should not be used, and discarded

- if the seal is broken,

- if the liquid is coloured or you can see particles floating in it,

- if you know, or think that it may have been accidentally frozen, or

- if there has been a refrigerator failure.

The product is for single use only. Only take one dose of Abseamed from each syringe. In case only a partial dose of the syringe is required, the cover should be removed before the plunger is pushed up to the desired numbered graduation mark to remove unwanted solution before injection. Refer to section 3. How to use Abseamed (instructions on how to inject Abseamed) of the package leaflet.

The pre-filled syringes are fitted with the PROTECSâ„¢ needle guard device to help prevent needle stick injuries after use. The package leaflet includes full instructions for the use and handling of pre-filled syringes with the PROTECSâ„¢ needle guard.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Frequently asked questions

What is Abseamed used for?

Abseamed is used in the management of anemia across several clinical settings, including anemia associated with chemotherapy, anemia in patients on hemodialysis, anemia linked to myelodysplastic conditions or lymphoma, and the reduction of allogeneic blood transfusion requirements around major surgery. Iron deficiency is also relevant in this context. The structured indication block below this introduction lists each registered use as recognised in the markets where Abseamed is authorised.

Which active substance is in Abseamed?

Abseamed contains epoetin alfa, a biologic classified within the antianemic, erythropoietic, and hematopoietic categories. Epoetin alfa is also distributed internationally under several other brand names, including biosimilar versions where regulators have approved them. The molecule itself is the same therapeutic substance regardless of the commercial label, although biologics are not interchangeable in the same way small-molecule generics are.

In how many countries is Abseamed available?

Abseamed is registered in 30 countries, with a footprint concentrated in the European Economic Area. Examples include Germany, Finland, Italy, Ireland, Greece, Hungary, and Iceland. Outside this regional cluster the brand is generally not encountered, although other epoetin alfa products are available in markets worldwide. If your country is not on this list, a local pharmacist or specialist can confirm what erythropoietic therapy is available regionally.

Are there other medications with the same active ingredient as Abseamed?

Epoetin alfa is marketed under several brand names internationally, including a number of biosimilar products approved in different regulatory regions. Other erythropoiesis-stimulating agents in the same broad pharmacological class also exist, although biologics within this category are not freely interchangeable and substitution is a clinical decision. To identify products available locally, search the active ingredient on Pill2Trip or speak with a treating specialist or pharmacist.

Should I consult a doctor before taking Abseamed?

Yes. Abseamed is a prescription biologic, and erythropoietic therapy is closely tied to laboratory monitoring, the underlying condition being treated, and individual patient factors. Prescription requirements, available brands, and biosimilar substitution rules vary significantly across countries, which is particularly relevant for travellers and patients relocating between regulatory regions. Any decision to start, continue, switch, or substitute this medication should be made with the healthcare team responsible for the patient's care.

Abseamed

Available in 30 countries